Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A First-in-human, Phase I, Open-label, Non-randomized, Multicentre Dose Escalation and Expansion Trial of BI 3810944 in Patients With Solid Tumours and Melanoma

NCT07224425 is registered in ClinicalTrials.gov with Boehringer Ingelheim as lead sponsor.

NCT NCT07224425
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07224425 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A First-in-human, Phase I, Open-label, Non-randomized, Multicentre Dose Escalation and Expansion Trial of BI 3810944 in Patients With Solid Tumours and Melanoma
Lead sponsor
Boehringer Ingelheim
Phase
Phase 1
Overall status
Recruiting
Start date
February 24, 2026
Completion date
October 5, 2029
Enrollment
69 (estimated)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

melanoma, solid tumours